AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients

[Business Wire] – AiCuris and Merck , known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent f more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merck is hiring next, click here to view